Waithaka, Rachael Wangeci, Janet Kerubo Maranga, and Celestine Khalechi Makobe. “Characterization of Extended Spectrum Beta-lactamase and Carbapenamase Producing Enterobacteriaceae Causing Urinary Tract Infection among Children in Kenya: A Cross-Sectional Study.” Advances in Microbiology 14, no. 7 (2024): 351-365. Research Projects Waithaka, Rachael Wangeci, Janet Kerubo Maranga, and Celestine Khalechi Makobe. “Characterization of Extended Spectrum Beta-lactamase and Carbapenamase Producing Enterobacteriaceae Causing Urinary Tract Infection among Children in Kenya: A Cross-Sectional Study.” Advances in Microbiology 14, no. 7 (2024): 351-365.
Lihanda, Bevin L. “The Economic Outcome of Antimicrobial Stewardship in a Hospital Setting: the Case of Gertrude’s Childrens’ Hospital.” PhD diss., University of Nairobi, 2023. Research Projects Lihanda, Bevin L. “The Economic Outcome of Antimicrobial Stewardship in a Hospital Setting: the Case of Gertrude’s Childrens’ Hospital.” PhD diss., University of Nairobi, 2023.
Juma, Bella. “Factors Affecting Haematological Parameters Before and After Introduction of Dolutegravir in Hiv-infected Children at Getrudes Childrens Hospital Comprehensive Care Clinic.” PhD diss., University of Nairobi, 2023 Research Projects Juma, Bella. “Factors Affecting Haematological Parameters Before and After Introduction of Dolutegravir in Hiv-infected Children at Getrudes Childrens Hospital Comprehensive Care Clinic.” PhD diss., University of Nairobi, 2023
2012 TADO – A phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease Case StudiesClosed out 2012 TADO – A phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease
2015/2016 HESTIA 1 – Multicenter, Open-label, Randomized, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging, Phase 2 Study of Ticagrelor followed by a Double-blind, randomized, Parallel group, Placebo-controlled 4 weeks extension Phase in Pediatric Patients with Sickle Cell Disease Case StudiesClosed out 2015/2016 HESTIA 1 – Multicenter, Open-label, Randomized, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging, Phase 2 Study of Ticagrelor followed by a Double-blind, randomized, Parallel group, Placebo-controlled 4 weeks extension Phase in Pediatric Patients with Sickle Cell Disease
2018 HESTIA 4 – A Multi-centre, Phase 1, Open-label, Single-Dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 months, with Sickle Cell Disease Case StudiesClosed out 2018 HESTIA 4 – A Multi-centre, Phase 1, Open-label, Single-Dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 months, with Sickle Cell Disease
2019 HESTIA 3 – A Randomised, Double-Blind, Parallel-Group, Multi-centre, Phase 3 Study to Evaluate the Effect of Ticagrelor vs Placebo in Reducing the Rate of Vaso-Occlusive Crises in Pediatric Patients with Sickle Cell Disease Case StudiesClosed out 2019 HESTIA 3 – A Randomised, Double-Blind, Parallel-Group, Multi-centre, Phase 3 Study to Evaluate the Effect of Ticagrelor vs Placebo in Reducing the Rate of Vaso-Occlusive Crises in Pediatric Patients with Sickle Cell Disease
2017 GBT 031 – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study of GBT 440 Administered Orally to Patients with Sickle Cell Disease Case StudiesClosed out 2017 GBT 031 – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study of GBT 440 Administered Orally to Patients with Sickle Cell Disease
